Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02312258
Registration number
NCT02312258
Ethics application status
Date submitted
5/12/2014
Date registered
9/12/2014
Date last updated
21/09/2023
Titles & IDs
Public title
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Query!
Scientific title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Query!
Secondary ID [1]
0
0
U1111-1160-1702
Query!
Secondary ID [2]
0
0
C16021
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Ixazomib
Placebo Comparator: Placebo - Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.
Experimental: Ixazomib - Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.
Treatment: Drugs: Placebo
Ixazomib placebo-matching capsules.
Treatment: Drugs: Ixazomib
Ixazomib capsules.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an independent review committee (IRC) according to International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first. Per IMWG criteria, PD is defined as, increase of 25% of lowest response value in one or more of following criteria: serum M-component (absolute increase =0.5 g/ deciliter (dL)); or urine M-component (absolute increase =200 mg/24-hour); difference between involved and uninvolved free light chains (FLC) levels (absolute increase >10 mg/dL); or bone marrow plasma cell percentage (absolute plasma cell percentage =10%); development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma; or development of hypercalcemia (corrected serum calcium >11.5mg/dL).
Query!
Timepoint [1]
0
0
From randomization until PD or death (up to 52 months)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was measured as the time from the date of randomization to the date of death.
Query!
Timepoint [1]
0
0
From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period
Query!
Assessment method [2]
0
0
Response was assessed according to IMWG criteria based on IRC assessment. Best response included PR, VGPR and CR. PR= >=50% reduction of serum M protein and >=90% or <200 mg reduction urinary M protein in 24-hour, or >50% decrease in difference between involved and uninvolved FLC levels, or >50% reduction in bone marrow plasma cells, if bone marrow plasma cells >30% and >50% reduction in size of soft tissue plasmacytomas at baseline. VGPR= >90% reduction (<100 mg/24-hour) in serum M-protein + urine M-protein detectable by immunofixation but not on electrophoresis. Complete response= >5% plasma cells in myelogram with absence of paraprotein in serum and urine according to immunofixation.
Query!
Timepoint [2]
0
0
Up to 27 months
Query!
Secondary outcome [3]
0
0
Time to Progression (TTP)
Query!
Assessment method [3]
0
0
TTP is defined as the time from the date of randomization to the date of first documentation of PD, using IMWG criteria.
Query!
Timepoint [3]
0
0
From randomization until PD or death (up to 52 months)
Query!
Secondary outcome [4]
0
0
Progression Free Survival 2 (PFS2)
Query!
Assessment method [4]
0
0
PFS2 is defined as the time from the date of randomization to objective PD on next-line treatment using IMWG criteria, or death due to any cause, whichever occurred first.
Query!
Timepoint [4]
0
0
From the date of randomization to every 12 weeks until second PD or death (up to 88 months)
Query!
Secondary outcome [5]
0
0
Time to Next Line Therapy (TTNT)
Query!
Assessment method [5]
0
0
TTNT is defined as the time from the date of randomization to the date of the first dose of next-line antineoplastic therapy.
Query!
Timepoint [5]
0
0
From randomization until PD or death (up to 52 months)
Query!
Secondary outcome [6]
0
0
Time to End of the Next-line of Therapy After Study Treatment
Query!
Assessment method [6]
0
0
Time to end of the next line of therapy is defined as the time from the date of randomization to the date of last dose of the next line of antineoplastic therapy following study treatment.
Query!
Timepoint [6]
0
0
From randomization until PD or death (up to 52 months)
Query!
Secondary outcome [7]
0
0
Duration of Next-line Therapy
Query!
Assessment method [7]
0
0
Duration of next-line therapy is defined as the time from the date of the first dose of the next line of antineoplastic therapy coming after study treatment to the date of the last dose.
Query!
Timepoint [7]
0
0
From randomization until PD or death (up to 52 months)
Query!
Secondary outcome [8]
0
0
Percentage of Participants Who Develop a New Primary Malignancy
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
From randomization until PD or death (up to 52 months)
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Conversion From Minimal Residual Disease (MRD) Positive to MRD Negative
Query!
Assessment method [9]
0
0
Bone marrow aspirates and blood samples were sent to a central laboratory and were assessed for MRD using flow cytometry. MRD negativity was defined as absence of MRD and MRD positivity was defined as presence of MRD. MRD was assessed by 8-color flow cytometry with the IMWG recommended sensitivity of 10^-5.
Query!
Timepoint [9]
0
0
Up to 52 months
Query!
Secondary outcome [10]
0
0
Correlation of MRD Status With PFS and OS
Query!
Assessment method [10]
0
0
PFS is defined as the time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurred first, assessed for up to 52 months in this outcome measure. OS was measured as the time from the date of randomization to the date of death, assessed for up to 52 months in this outcome measure. Participants with various types of known MRD status were pooled together for analysis of overall survival in this outcome measure.
Query!
Timepoint [10]
0
0
From randomization up to 52 months
Query!
Secondary outcome [11]
0
0
OS in a High-risk Population
Query!
Assessment method [11]
0
0
High-risk population included but not be limited to participants carrying cytogenetic deletion (del)17, translocation [t](4;14), t(14;16). OS was measured as the time from the date of randomization to the date of death.
Query!
Timepoint [11]
0
0
From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)
Query!
Secondary outcome [12]
0
0
PFS in a High-risk Population
Query!
Assessment method [12]
0
0
High-risk population included but not be limited to participants carrying del17, t(4;14), t(14;16). PFS was defined as the time from the date of randomization to the date of first documentation of PD or death from any cause.
Query!
Timepoint [12]
0
0
From randomization until PD or death (up to 52 months)
Query!
Secondary outcome [13]
0
0
Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
Query!
Assessment method [13]
0
0
ECOG performance status assesses a participant's performance status on a 6-point scale ranging from 0=fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair >50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead. Lower grades indicate improvement.
Query!
Timepoint [13]
0
0
Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26, progression free survival follow-up (PFSFU)- Visit 37 and progressive disease follow-up (PDFU)- Visit 26 (cycle length=28 days)
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [14]
0
0
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs were defined as events that occurred after administration of the first dose of ixazomib or placebo through 30 days after the last dose of ixazomib or placebo. A SAE means any untoward medical occurrence that resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was considered medically significant.
Query!
Timepoint [14]
0
0
First dose of study drug through 30 days after last dose of study drug (up to 88 months)
Query!
Secondary outcome [15]
0
0
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS)
Query!
Assessment method [15]
0
0
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The change from baseline in GHS (EORTC QLQ-C30) score is presented. Participant responses to the question "How would you rate your overall health during the past week?" are scored on a 7-point scale (1=very poor to 7=excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall GHS.
Query!
Timepoint [15]
0
0
Baseline, Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 (cycle length=28 days)
Query!
Secondary outcome [16]
0
0
Correlation Between Frailty Status and PFS and OS
Query!
Assessment method [16]
0
0
Participant's frailty status is classified as fit, unfit or frail on the bases of 4 components: age, the Charlson comorbidity scoring system without age weighting, the Katz index of independence in activities of daily living, and the Lawton instrumental activities of daily living scale. The sum of the 4 frailty scores equals the total frailty score. A total frailty score of 0 corresponds to a frailty status of fit; a total score of 1, to unfit; and a total score of 2 or more, to frail. PFS is defined as the time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurs first, assessed for up to 52 months in this outcome measure. OS will be measured as the time from the date of randomization to the date of death, assessed for up to 52 months in this outcome measure.
Query!
Timepoint [16]
0
0
From randomization up to 52 months
Query!
Secondary outcome [17]
0
0
Pharmacokinetic Parameter: Plasma Concentration of Ixazomib
Query!
Assessment method [17]
0
0
Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay.
Query!
Timepoint [17]
0
0
Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days)
Query!
Secondary outcome [18]
0
0
Time to Resolution of Peripheral Neuropathy (PN) Events
Query!
Assessment method [18]
0
0
PN is defined as the event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the medical dictionary for regulatory activities (MedDRA). A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. Time to resolution was defined as the time from the initial onset date (inclusive) to the resolution date for resolved events.
Query!
Timepoint [18]
0
0
Up to 52 months
Query!
Secondary outcome [19]
0
0
Time to Improvement of PN Events
Query!
Assessment method [19]
0
0
PN is defined as the event in the high-level term of peripheral neuropathies NEC according to the MedDRA. A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the improvement date or the day before and after. Time to improvement was defined as the time from the initial onset date (inclusive) to the improvement of event.
Query!
Timepoint [19]
0
0
Up to 52 months
Query!
Eligibility
Key inclusion criteria
1. Adult male or female participants 18 years or older with a confirmed diagnosis of
symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria.
2. Completed 6 to 12 months (± 2 weeks) of initial therapy, during which the participant
was treated to best response, defined as the best response maintained for 2 cycles
after the M-protein nadir is reached.
3. Documented major response (PR, VGPR, CR) according to the International Myeloma
Working Group (IMWG) uniform response criteria, version 2011, after this initial
therapy.
4. Female participants who:
- Are postmenopausal for at least 1 year before the screening visit, OR
- Are surgically sterile, OR
- If they are of childbearing potential, agree to practice 2 effective methods of
contraception, at the same time, from the time of signing the informed consent
through 90 days after the last dose of study drug, OR
- Agree to practice true abstinence, when this is in line with the preferred and
usual lifestyle of the participant. (Periodic abstinence [eg, calendar,
ovulation, symptothermal, postovulation methods] and withdrawal are not
acceptable methods of contraception.)
Male participants, even if surgically sterilized (that is, status postvasectomy), who:
- Agree to practice effective barrier contraception during the entire study
Treatment period and through 90 days after the last dose of study drug, OR
- Agree to practice true abstinence, when this is in line with the preferred and
usual lifestyle of the participant. (Periodic abstinence [example, calendar,
ovulation, symptothermal, postovulation methods for the female partner] and
withdrawal are not acceptable methods of contraception.)
5. Voluntary written consent must be given before performance of any study-related
procedure not part of standard medical care, with the understanding that consent may
be withdrawn by the participant at any time without prejudice to future medical care.
6. Complete documentation of the details of the initial therapy before randomization
including cytogenetics and International Staging System (ISS) is available.
7. Eastern Cooperative Oncology Group Performance Status of 0 to 2.
8. Suitable venous access for the study-required blood sampling and consent for the
specific amounts that will be taken.
9. Is willing and able to adhere to the study visit schedule and other protocol
requirements including blood sampling and bone marrow aspiration.
10. Must meet the following clinical laboratory criteria at study entry:
- Absolute neutrophil count (ANC) greater than or equal to (=) 1,000 per cubic
millimeter (/mm^3) without growth factor support and platelet count =75,000/mm^3.
Platelet transfusions to help participants meet eligibility criteria are not
allowed within 3 days before randomization.
- Total bilirubin less than or equal to (=) 1.5*the upper limit of the normal range
(ULN).
- Alanine aminotransferase and aspartate aminotransferase = 3*ULN.
- Calculated creatinine clearance = 30 milliliter per minute (mL/min) (using the
Cockcroft-Gault equation).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Multiple myeloma that has relapsed after, or was not responsive to, initial therapy.
2. Prior SCT.
3. Radiotherapy within 14 days before randomization.
4. Diagnosed or treated for another malignancy within 5 years before randomization or
previous diagnosis with another malignancy. Participants with nonmelanoma skin cancer
or carcinoma in situ of any type are not excluded if they have undergone complete
resection.
5. Female participants who are lactating and breastfeeding or have a positive serum
pregnancy test during the Screening period.
6. Major surgery within 14 days before randomization.
7. Central nervous system involvement.
8. Infection requiring intravenous (IV) antibiotic therapy or other serious infection
within 14 days before randomization.
9. Diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly,
endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS), plasma cell
leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative
syndrome.
10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure,
unstable angina, or myocardial infarction within the past 6 months.
11. Systemic treatment with strong cytochrome P450 3A (CYP3A) inducers (rifampin,
rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or St. John's wort
within 14 days before randomization.
12. Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active
hepatitis B or C infection.
13. Comorbid systemic illnesses or other severe concurrent disease that, in the judgment
of the investigator, would make the participant inappropriate for entry into this
study or interfere significantly with the proper assessment of safety and toxicity of
the prescribed regimens (example, PN that is Grade 1 with pain or Grade 2 or higher of
any cause).
14. Psychiatric illness or social situation that would limit compliance with study
requirements.
15. Known allergy to any of the study medications, their analogues, or excipients in the
various formulations of any agent.
16. Inability to swallow oral medication, inability or unwillingness to comply with the
drug administration requirements, or gastrointestinal (GI) procedure that could
interfere with the oral absorption or tolerance of treatment.
17. Treatment with any investigational products within 30 days before randomization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/04/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/08/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
706
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
St Vincents Hospital Melbourne - PPDS - Fitzroy
Query!
Recruitment hospital [2]
0
0
Frankston Hospital - Frankston
Query!
Recruitment hospital [3]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [2]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Iowa
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maine
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Washington
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
West Virginia
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Ciudad Autonoma De BuenosAires
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Cordoba
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Santa Fe
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Tirol
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Salzburg
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Wels
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Wien
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Brussels
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Bahia
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Goias
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Minas Gerais
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Parana
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Rio Grande Do Norte
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Rio Grande Do Sul
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Santa Catarina
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Sao Paulo
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Rio De Janeiro
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Rio de Janeiro
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Sao Jose Do Rio Preto
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Chile
Query!
State/province [37]
0
0
Araucanía
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
Santiago
Query!
Country [39]
0
0
Chile
Query!
State/province [39]
0
0
Vina Del Mar
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Jiangsu
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Shanghai
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Zhejiang
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Beijing
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Hangzhou
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Shenyang
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Taiyuan
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Wuhan
Query!
Country [48]
0
0
Colombia
Query!
State/province [48]
0
0
Antioquia
Query!
Country [49]
0
0
Colombia
Query!
State/province [49]
0
0
Cundinamarca
Query!
Country [50]
0
0
Colombia
Query!
State/province [50]
0
0
Distrito Capital De Bogota
Query!
Country [51]
0
0
Croatia
Query!
State/province [51]
0
0
Grad Zagreb
Query!
Country [52]
0
0
Croatia
Query!
State/province [52]
0
0
Rijeka
Query!
Country [53]
0
0
Croatia
Query!
State/province [53]
0
0
Zagreb
Query!
Country [54]
0
0
Czechia
Query!
State/province [54]
0
0
Kralovehradeck Kraj
Query!
Country [55]
0
0
Czechia
Query!
State/province [55]
0
0
Praha, Hlavni Mesto
Query!
Country [56]
0
0
Czechia
Query!
State/province [56]
0
0
Brno
Query!
Country [57]
0
0
Czechia
Query!
State/province [57]
0
0
Olomouc
Query!
Country [58]
0
0
Czechia
Query!
State/province [58]
0
0
Ostrava
Query!
Country [59]
0
0
Czechia
Query!
State/province [59]
0
0
Praha 2
Query!
Country [60]
0
0
Denmark
Query!
State/province [60]
0
0
Capital
Query!
Country [61]
0
0
Denmark
Query!
State/province [61]
0
0
Aarhus N
Query!
Country [62]
0
0
Denmark
Query!
State/province [62]
0
0
Holstebro
Query!
Country [63]
0
0
Denmark
Query!
State/province [63]
0
0
Odense
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Hauts-de-Seine
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Loire-Atlantique
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Meurthe-et-Moselle
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Dijon
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Lille
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Paris
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Pessac
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Poitiers
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Rennes
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Baden-Wurttemberg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Bayern
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Niedersachsen
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Nordrhein-Westfalen
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Rheinland-Pfalz
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Saarland
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Aschaffenburg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Berlin
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Landshut
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Munchen
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Rosenheim
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Wurzburg
Query!
Country [85]
0
0
Greece
Query!
State/province [85]
0
0
Attiki
Query!
Country [86]
0
0
Greece
Query!
State/province [86]
0
0
Athens
Query!
Country [87]
0
0
Greece
Query!
State/province [87]
0
0
Ioannina
Query!
Country [88]
0
0
Greece
Query!
State/province [88]
0
0
Larissa
Query!
Country [89]
0
0
Greece
Query!
State/province [89]
0
0
Thessaloniki
Query!
Country [90]
0
0
Hungary
Query!
State/province [90]
0
0
Budapest
Query!
Country [91]
0
0
Hungary
Query!
State/province [91]
0
0
Debrecen
Query!
Country [92]
0
0
Hungary
Query!
State/province [92]
0
0
Szeged
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Be'er Sheva
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Beer Yaakov
Query!
Country [95]
0
0
Israel
Query!
State/province [95]
0
0
Haifa
Query!
Country [96]
0
0
Israel
Query!
State/province [96]
0
0
Jerusalem
Query!
Country [97]
0
0
Israel
Query!
State/province [97]
0
0
Kfar Saba
Query!
Country [98]
0
0
Israel
Query!
State/province [98]
0
0
Petah Tikva
Query!
Country [99]
0
0
Israel
Query!
State/province [99]
0
0
Ramat Gan
Query!
Country [100]
0
0
Israel
Query!
State/province [100]
0
0
Tel Aviv
Query!
Country [101]
0
0
Israel
Query!
State/province [101]
0
0
Tiberias
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Campania
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Emilia-Romagna
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Liguria
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Lombardia
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Puglia
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Sicilia
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Toscana
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Umbria
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Ancona
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Firenze
Query!
Country [112]
0
0
Italy
Query!
State/province [112]
0
0
Parma
Query!
Country [113]
0
0
Italy
Query!
State/province [113]
0
0
Ravenna
Query!
Country [114]
0
0
Italy
Query!
State/province [114]
0
0
Torino
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Gihu
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Hyogo
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Ibaraki
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Nara
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Okayama
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Tokyo
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Fukuoka
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Fukushima-City
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Kurume
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Nagaizumi-cho
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Nagoya
Query!
Country [126]
0
0
Japan
Query!
State/province [126]
0
0
Narita-shi
Query!
Country [127]
0
0
Japan
Query!
State/province [127]
0
0
Niigata-city
Query!
Country [128]
0
0
Japan
Query!
State/province [128]
0
0
Osaka
Query!
Country [129]
0
0
Japan
Query!
State/province [129]
0
0
Tachikawa
Query!
Country [130]
0
0
Japan
Query!
State/province [130]
0
0
Toyohashi
Query!
Country [131]
0
0
Japan
Query!
State/province [131]
0
0
Yamanashi
Query!
Country [132]
0
0
Korea, Republic of
Query!
State/province [132]
0
0
Gyeonggido
Query!
Country [133]
0
0
Korea, Republic of
Query!
State/province [133]
0
0
Incheon
Query!
Country [134]
0
0
Korea, Republic of
Query!
State/province [134]
0
0
Seoul
Query!
Country [135]
0
0
Mexico
Query!
State/province [135]
0
0
Jalisco
Query!
Country [136]
0
0
Mexico
Query!
State/province [136]
0
0
Nuevo Leon
Query!
Country [137]
0
0
Mexico
Query!
State/province [137]
0
0
Mexico City
Query!
Country [138]
0
0
Mexico
Query!
State/province [138]
0
0
Oaxaca
Query!
Country [139]
0
0
Poland
Query!
State/province [139]
0
0
Kujawsko-pomorskie
Query!
Country [140]
0
0
Poland
Query!
State/province [140]
0
0
Mazowieckie
Query!
Country [141]
0
0
Poland
Query!
State/province [141]
0
0
Chorzow
Query!
Country [142]
0
0
Poland
Query!
State/province [142]
0
0
Wroclaw
Query!
Country [143]
0
0
Portugal
Query!
State/province [143]
0
0
Lisboa
Query!
Country [144]
0
0
Portugal
Query!
State/province [144]
0
0
Almada
Query!
Country [145]
0
0
Portugal
Query!
State/province [145]
0
0
Braga
Query!
Country [146]
0
0
Portugal
Query!
State/province [146]
0
0
Porto
Query!
Country [147]
0
0
Russian Federation
Query!
State/province [147]
0
0
Kirov
Query!
Country [148]
0
0
Russian Federation
Query!
State/province [148]
0
0
Pyatigorsk
Query!
Country [149]
0
0
Russian Federation
Query!
State/province [149]
0
0
Ryazan
Query!
Country [150]
0
0
Russian Federation
Query!
State/province [150]
0
0
St. Petersburg
Query!
Country [151]
0
0
Serbia
Query!
State/province [151]
0
0
Belgrade
Query!
Country [152]
0
0
Serbia
Query!
State/province [152]
0
0
Kragujevac
Query!
Country [153]
0
0
Serbia
Query!
State/province [153]
0
0
Nis
Query!
Country [154]
0
0
Singapore
Query!
State/province [154]
0
0
Singapore
Query!
Country [155]
0
0
South Africa
Query!
State/province [155]
0
0
Gauteng
Query!
Country [156]
0
0
Spain
Query!
State/province [156]
0
0
Barcelona
Query!
Country [157]
0
0
Spain
Query!
State/province [157]
0
0
Madrid, Communidad Delaware
Query!
Country [158]
0
0
Spain
Query!
State/province [158]
0
0
Navarra
Query!
Country [159]
0
0
Spain
Query!
State/province [159]
0
0
Madrid
Query!
Country [160]
0
0
Spain
Query!
State/province [160]
0
0
Murcia
Query!
Country [161]
0
0
Spain
Query!
State/province [161]
0
0
Salamanca
Query!
Country [162]
0
0
Spain
Query!
State/province [162]
0
0
Valencia
Query!
Country [163]
0
0
Sweden
Query!
State/province [163]
0
0
Sodermanlands Lan
Query!
Country [164]
0
0
Sweden
Query!
State/province [164]
0
0
Vastra Gotalands Lan
Query!
Country [165]
0
0
Sweden
Query!
State/province [165]
0
0
Lund
Query!
Country [166]
0
0
Switzerland
Query!
State/province [166]
0
0
Thun
Query!
Country [167]
0
0
Taiwan
Query!
State/province [167]
0
0
Kaohsiung
Query!
Country [168]
0
0
Taiwan
Query!
State/province [168]
0
0
Taichung
Query!
Country [169]
0
0
Taiwan
Query!
State/province [169]
0
0
Taipei
Query!
Country [170]
0
0
Thailand
Query!
State/province [170]
0
0
Krung Thep Maha Nakhon
Query!
Country [171]
0
0
Thailand
Query!
State/province [171]
0
0
Bangkok
Query!
Country [172]
0
0
Thailand
Query!
State/province [172]
0
0
Chiangmai
Query!
Country [173]
0
0
Turkey
Query!
State/province [173]
0
0
Ankara
Query!
Country [174]
0
0
Turkey
Query!
State/province [174]
0
0
Istanbul
Query!
Country [175]
0
0
Turkey
Query!
State/province [175]
0
0
Izmir
Query!
Country [176]
0
0
United Kingdom
Query!
State/province [176]
0
0
Antrim
Query!
Country [177]
0
0
United Kingdom
Query!
State/province [177]
0
0
Birmingham
Query!
Country [178]
0
0
United Kingdom
Query!
State/province [178]
0
0
Bristol, City Of
Query!
Country [179]
0
0
United Kingdom
Query!
State/province [179]
0
0
Dorset
Query!
Country [180]
0
0
United Kingdom
Query!
State/province [180]
0
0
Hampshire
Query!
Country [181]
0
0
United Kingdom
Query!
State/province [181]
0
0
Kent
Query!
Country [182]
0
0
United Kingdom
Query!
State/province [182]
0
0
London, City Of
Query!
Country [183]
0
0
United Kingdom
Query!
State/province [183]
0
0
Oxfordshire
Query!
Country [184]
0
0
United Kingdom
Query!
State/province [184]
0
0
Staffordshire
Query!
Country [185]
0
0
United Kingdom
Query!
State/province [185]
0
0
Surrey
Query!
Country [186]
0
0
United Kingdom
Query!
State/province [186]
0
0
Bath
Query!
Country [187]
0
0
United Kingdom
Query!
State/province [187]
0
0
Belfast
Query!
Country [188]
0
0
United Kingdom
Query!
State/province [188]
0
0
Bristol
Query!
Country [189]
0
0
United Kingdom
Query!
State/province [189]
0
0
Cardiff
Query!
Country [190]
0
0
United Kingdom
Query!
State/province [190]
0
0
Isleworth
Query!
Country [191]
0
0
United Kingdom
Query!
State/province [191]
0
0
Leicester
Query!
Country [192]
0
0
United Kingdom
Query!
State/province [192]
0
0
London
Query!
Country [193]
0
0
United Kingdom
Query!
State/province [193]
0
0
Manchester
Query!
Country [194]
0
0
United Kingdom
Query!
State/province [194]
0
0
Middlesex
Query!
Country [195]
0
0
United Kingdom
Query!
State/province [195]
0
0
Oldham
Query!
Country [196]
0
0
United Kingdom
Query!
State/province [196]
0
0
Southall
Query!
Country [197]
0
0
United Kingdom
Query!
State/province [197]
0
0
Swansea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Takeda
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine the effect of ixazomib maintenance therapy on
progression free survival (PFS) compared with placebo, in participants with NDMM who have had
a major response (complete response [CR], very good partial response [VGPR], or partial
response [PR]) to initial therapy and who have not undergone SCT.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02312258
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Takeda
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02312258
Download to PDF